Last edition
News about "unresectable hepatocellular carcinoma treatment"
CDSCO Approves AstraZeneca Pharma India's Durvalumab for uHCC Treatment
AstraZeneca Pharma India has received CDSCO approval for durvalumab to treat unresectable hepatocellular carcinoma (uHCC), a major global health concern as HCC ranks among the most common and deadliest cancers worldwide.
Unresectable Hepatocellular Carcinoma Treatment | 18/03/2026 | By Akanki
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members